Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to Sell at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities research analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday,Finviz reports. They currently have a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $15.00. The Goldman Sachs Group’s target price indicates a potential downside of 9.09% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. HC Wainwright upped their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $13.20 on Tuesday. The firm’s fifty day moving average is $12.81 and its two-hundred day moving average is $11.90. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $13.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.74 billion, a P/E ratio of 101.55 and a beta of 1.32.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently modified their holdings of DVAX. GAMMA Investing LLC lifted its stake in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares in the last quarter. US Bancorp DE grew its holdings in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the third quarter valued at approximately $45,000. Finally, Nisa Investment Advisors LLC lifted its stake in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.